2001年～2003年重庆市18家医院β-内酰胺酶抑制剂复合制剂利用分析  

Analysis of Consumption of Antibiotic/Beta-Lactamase Inhibitor Preparations in18Hospitals of Chongqing During the2001～2003Period

作　　者：彭永富[1] 夏培元[1] 刘松青[1] 

机构地区：[1]第三军医大学西南医院药学部,重庆市400038

出　　处：《中国药房》2005年第1期39-41,共3页China Pharmacy

摘　　要：目的 :评估 β-内酰胺酶抑制剂复合制剂的利用现状及其发展趋势。方法 :调查重庆市18家医院在2001年～2003年应用β-内酰胺酶抑制剂复合制剂的组成、剂型、规格、药品名称、生产厂商、用药金额等 ,分析其临床应用情况。结果 :β-内酰胺酶抑制剂复合制剂在2001、2002、2003年的用药金额分别为2229、2937、4119万元 ,年平均增长率为26.41% ;3年中与舒巴坦、克拉维酸、他唑巴坦的复合制剂金额分别为6280、2276、729万元 ,占该类药物总金额的67.64 %、24.51%、7.85% ,年平均增长率分别为32.20%、35.93%、94.50 %。结论 :β-内酰胺酶抑制剂复合制剂的用药量逐年快速增长 ,预计其市场需求量还会进一步上升。OBJECTIVE:To survey and evaluate the current situation and developing trend of antibiotic/beta-lactamase inhibitor(BLI)preparations consumed.METHODS:The antibiotic/BLI preparations used in18hospitals of Chongqing in2001～2003were collected in respect to the compositions,dosage forms,specifications,drug name,manufacturers and sum of money for consumption,and the clinical application information was analysed.RESULTS:The sum of money for these antibiˉotics/BLI consumed in the years2001,2002and2003were2229,2937and4119ten-thousand yuan(RMB),respectively,with an average annual increase rate of26.41%.Among them the consumption costs of antibiotics plus sulbactam,clavulanate and tazobactam were6280,2276and729ten-thousand yuan(RMB),accounting for67.64%,24.51%and7.85%of the total consumption sum,with an annual increase rates of32.20%,35.93%and94.50%,respectively.CONCLUSION:The consumpˉtion of the antibiotic/BLI preparations was increasing fast in these years and the more requirement for the antibiotic/BLI preparations by market would be expected in the future.

关 键 词：Β-内酰胺酶抑制剂 舒巴坦 克拉维酸 他唑巴坦 用药分析 

分 类 号：R978.11[医药卫生—药品]